t(10;10)(p12;q21) CTNNA3/ARHGAP21 by Huret, Jean-Loup
Leukaemia Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2019; 23(11) 337 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
t(10;10)(p12;q21) CTNNA3/ARHGAP21 
Jean Loup Huret 
jean-loup.huret@atlasgeneticsoncology.org 
Published in Atlas Database: August 2018 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t1010p12q21ID1835.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70610/08-2018-t1010p12q21ID1835.pdf 
DOI: 10.4267/2042/70610
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on t(10;10)(p12;q21) , with data on clinics 
and the genes involved 
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Clinics and pathology 
Disease 
Early T-cell precursor acute lymphoblastic 
leukaemia 
Epidemiology 
Only one case to date, a 7-year old boy (Zhang et al. 
2012). 
Evolution 
Outcome: relapse with lineage switch at 13 months 




The karyotype was complex, with a constitutional 
inv(2)(p11.2q13), a del(1p), and other abnormalities. 
Genes involved and 
proteins 




The transcript has 26 exons. 
Protein 
1958 amino acids (aa). ARHGAP21 acts as a Rho 
GTPase-activating protein for RHOA, RHOC and 
CDC42, ARHGAP21 plays a role in cell 
proliferation, migration, vesicle traffic, cell 
adhesions and insulin secretion. ARHGAP21 is 
implicated in many tumor tissues (Ferreira Pissarra 




The transcript has 18 exons. 
Protein 
895 aa for the longest isoform. CTNNA3 is an α-
catenin. CTNNA3 plays a role in cell-cell adhesion: 
catenins link the single-pass type I transmembrane 
linker proteins cadherins (cell-cell adhesion 
molecule expressed in adherents junctions) to the 
actin filament network. α-catenins bind the 
cytoplasmic domains of cadherins through β-catenin 
to actin filaments.  
An heterozygous constitutional (germline) deletion 
of CTNNA3 was found in a hybrid neurofibroma/ 
schwannoma of a patient with clinically diagnosed 
neurofibromatosis type 2. Loss of CTNNA3 protein 
expression was found in neurofibromas, 
schwannomas, and malignant peripheral nerve 
sheath tumors. Depletion of CTNNA3 in Schwann 
cells was associated with reduced RNA of CDH1 (E-
cadherin) via induction of SNA1, SNAI2 (E-
cadherin repressors) as well as disaggregation of the 
actin cytoskeleton and epithelial-mesenchymal 
transition promotion  
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CTNNA3, is a tumor suppressor in hepatocellular 
carcinoma, inhibiting the proliferation, migration an 
d invasion. CTNNA3 inhibited AKT signal, and in 
turn decreased PCNA and MMP9, and increased the 
cell cycle inhibitor CDKN1A (p21Cip1/Waf1). 
CTNNA3 is also frequently mutated in laryngeal 
carcinomas and low-expressed in urothelial 
carcinoma of the bladder.  
Other α-catenins, CTNNA1and CTNNA2 are also 
frequently mutated (loss of function) in various 
cancers  
CTNNA3 is inhibited by MIR425 (He et al., 2016; 
Stahn et al., 2016).. 
Result of the chromosomal 
anomaly 
Hybrid gene 
t(10;10)(p12;q21) CTNNA3/ARHGAP21 but no 
fusion transcript was detectable. 
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